MNKD MannKind Corporation

1.27
-0.02  -2%
Previous Close 1.29
Open 1.3
Price To Book -1.23
Market Cap 240,812,480
Shares 189,616,126
Volume 873,658
Short Ratio
Av. Daily Volume 2,350,722
Stock charts supplied by TradingView

NewsSee all news

  1. MannKind Corporation to Present at the 2019 Cantor Global Healthcare Conference

    WESTLAKE VILLAGE, Calif., Sept. 26, 2019 (GLOBE NEWSWIRE) -- MannKind Corporation (NASDAQ:MNKD), a company focused on the development and commercialization of inhaled therapeutic products for patients with diseases

  2. MannKind Presents Positive Afrezza® Clinical Data from Type 1 Diabetes Study at 55th Annual Meeting of the EASD

    WESTLAKE VILLAGE, Calif., Sept. 19, 2019 (GLOBE NEWSWIRE) -- MannKind Corporation (NASDAQ:MNKD) announced that data from a one-year study of Afrezza® (insulin human) Inhalation Powder was presented at the 55th Annual

  3. MannKind Corporation to Present at H.C. Wainwright 21st Annual Global Investment Conference

    WESTLAKE VILLAGE, Calif., Aug. 30, 2019 (GLOBE NEWSWIRE) -- MannKind Corporation (NASDAQ:MNKD), a company focused on the development and commercialization of inhaled therapeutic products for patients with diseases such

Drug Information

Drug catalyst information is displayed when you hover over / tap on the stage bar graph.

Approved June 27, 2014.
AFREZZA
Type 1/2 diabetes
Phase 1 trial completion announced June 7, 2018.
Treprostinil Technosphere
Pulmonary Arterial Hypertension (PAH)

Latest News

  1. MannKind Corporation to Present at the 2019 Cantor Global Healthcare Conference

    WESTLAKE VILLAGE, Calif., Sept. 26, 2019 (GLOBE NEWSWIRE) -- MannKind Corporation (NASDAQ:MNKD), a company focused on the development and commercialization of inhaled therapeutic products for patients with diseases

  2. MannKind Presents Positive Afrezza® Clinical Data from Type 1 Diabetes Study at 55th Annual Meeting of the EASD

    WESTLAKE VILLAGE, Calif., Sept. 19, 2019 (GLOBE NEWSWIRE) -- MannKind Corporation (NASDAQ:MNKD) announced that data from a one-year study of Afrezza® (insulin human) Inhalation Powder was presented at the 55th Annual

  3. MannKind Corporation to Present at H.C. Wainwright 21st Annual Global Investment Conference

    WESTLAKE VILLAGE, Calif., Aug. 30, 2019 (GLOBE NEWSWIRE) -- MannKind Corporation (NASDAQ:MNKD), a company focused on the development and commercialization of inhaled therapeutic products for patients with diseases such